Buy Rasburnat : Rasburicase 1.5 Mg Injection Online

Description

Description:

Rasburnat is a medication manufactured by Nato Pharma Ltd., containing the active ingredient Rasburicase. Each injection typically contains 1.5 mg of Rasburicase. Rasburicase is a recombinant urate oxidase enzyme used for the treatment of hyperuricemia (high levels of uric acid) associated with tumor lysis syndrome (TLS) in patients receiving cancer chemotherapy.

Indications:

Rasburnat is indicated for the initial management of plasma uric acid levels in adult and pediatric patients (including neonates) with leukemia, lymphoma, and solid tumor malignancies who are at risk for tumor lysis syndrome (TLS) and subsequent acute renal failure. It is specifically used for the following conditions:

1. Tumor Lysis Syndrome (TLS): Rasburnat is used to prevent and treat hyperuricemia associated with TLS, a potentially life-threatening complication of cancer chemotherapy characterized by the rapid release of intracellular components (such as nucleic acids) into the bloodstream, leading to metabolic abnormalities and kidney damage.

How It Works:

Rasburicase works by catalyzing the enzymatic oxidation of uric acid into allantoin, a more soluble and easily excreted compound, thereby reducing serum uric acid levels. By converting uric acid to allantoin, Rasburicase helps to prevent the formation of uric acid crystals and the subsequent deposition of urate crystals in the kidneys and other tissues, reducing the risk of renal impairment and other complications associated with hyperuricemia.

Dosage and Administration:

The dosage of Rasburnat depends on the patient’s body weight and the degree of hyperuricemia. It is administered intravenously as directed by a healthcare professional, usually as a single dose. The recommended dosage regimen is typically based on the patient’s body weight, with adjustments made for pediatric patients and those with renal impairment.

Possible Side Effects:

Common side effects of Rasburnat may include:

1. Infusion Reactions: Some patients may experience infusion-related reactions, such as fever, chills, nausea, vomiting, headache, and dizziness.
2. Hypersensitivity Reactions: Rarely, Rasburnat can cause hypersensitivity reactions, including rash, itching, hives, bronchospasm, and anaphylaxis.
3. Hemolysis: Rasburicase can induce hemolysis (breakdown of red blood cells), leading to anemia and jaundice, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
4. Methemoglobinemia: Rasburicase may cause methemoglobinemia, a condition characterized by elevated levels of methemoglobin in the blood, leading to cyanosis (bluish discoloration of the skin) and hypoxia.
5. Electrolyte Abnormalities: Rasburnat can cause electrolyte abnormalities, including hypocalcemia, hypophosphatemia, and hypokalemia.

Warnings and Precautions:

1. Hypersensitivity: Patients should be monitored for signs and symptoms of hypersensitivity reactions during and after administration of Rasburnat. Treatment should be discontinued if a severe hypersensitivity reaction occurs.
2. Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: Rasburnat should be used with caution in patients with G6PD deficiency, as it can precipitate hemolysis.
3. Methemoglobinemia: Patients should be monitored for signs and symptoms of methemoglobinemia, particularly in those with predisposing factors such as concomitant use of oxidizing agents or in patients with methemoglobin reductase deficiency.
4. Renal Impairment: Rasburnat should be used with caution in patients with renal impairment, as it can exacerbate electrolyte abnormalities and increase the risk of adverse reactions.

Rasburnat by Nato Pharma Ltd. is a prescription medication used for the management of hyperuricemia associated with tumor lysis syndrome (TLS) in patients receiving cancer chemotherapy. Patients should follow their healthcare provider’s instructions regarding dosage, administration, and monitoring for adverse effects. Any concerns or potential side effects should be discussed with a healthcare professional.